- Home
- RNXT vs BRNS Comparison
RNXT vs BRNS Comparison
Compare RNXT & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- BRNS
- Stock Information
- Founded
- RNXT 2012
- BRNS 2016
- Country
- RNXT United States
- BRNS United Kingdom
- Employees
- RNXT N/A
- BRNS N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- BRNS Health Care
- Exchange
- RNXT Nasdaq
- BRNS Nasdaq
- Market Cap
- RNXT 44.6M
- BRNS 42.8M
- IPO Year
- RNXT 2021
- BRNS 2021
- Fundamental
- Price
- RNXT $1.14
- BRNS $1.34
- Analyst Decision
- RNXT Strong Buy
- BRNS Strong Buy
- Analyst Count
- RNXT 2
- BRNS 1
- Target Price
- RNXT $7.25
- BRNS $3.00
- AVG Volume (30 Days)
- RNXT 107.8K
- BRNS 3.8M
- Earning Date
- RNXT 08-14-2025
- BRNS 08-07-2025
- Dividend Yield
- RNXT N/A
- BRNS N/A
- EPS Growth
- RNXT N/A
- BRNS N/A
- EPS
- RNXT N/A
- BRNS N/A
- Revenue
- RNXT $240,000.00
- BRNS $14,969,000.00
- Revenue This Year
- RNXT $3,104.65
- BRNS N/A
- Revenue Next Year
- RNXT $301.89
- BRNS N/A
- P/E Ratio
- RNXT N/A
- BRNS N/A
- Revenue Growth
- RNXT N/A
- BRNS 1766.46
- 52 Week Low
- RNXT $0.75
- BRNS $0.64
- 52 Week High
- RNXT $1.69
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- RNXT 33.69
- BRNS 49.37
- Support Level
- RNXT $1.23
- BRNS $1.28
- Resistance Level
- RNXT $1.28
- BRNS $1.45
- Average True Range (ATR)
- RNXT 0.06
- BRNS 0.17
- MACD
- RNXT -0.01
- BRNS -0.05
- Stochastic Oscillator
- RNXT 15.00
- BRNS 8.22
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.